These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8728650)

  • 61. Liposomes as vehicles for the presentation of a synthetic peptide containing an epitope of hepatitis A virus.
    García M; Alsina MA; Reig F; Haro I
    Vaccine; 1999 Sep; 18(3-4):276-83. PubMed ID: 10506652
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mapping of dominant B-cell epitopes of a human zona pellucida protein (ZP1).
    Skinner SM; Schwoebel ES; Prasad SV; Oguna M; Dunbar BS
    Biol Reprod; 1999 Dec; 61(6):1373-80. PubMed ID: 10569978
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Peptide-based synthetic recombinant vaccines with anti-viral efficacy.
    Arnon R; Tarrab-Hazdai R; Ben-Yedidia T
    Biologicals; 2001; 29(3-4):237-42. PubMed ID: 11851322
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Solution structure of the all L- and D-amino acid-substituted mucin 2 epitope peptides.
    Toke O; Tugyi R; Uray K; Hudecz F
    Biochem Biophys Res Commun; 2007 Jul; 358(3):739-42. PubMed ID: 17509526
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A synthetic peptide spontaneously self-assembles to reconstruct a group-specific, conformational determinant of hepatitis B surface antigen.
    Manivel V; Ramesh R; Panda SK; Rao KV
    J Immunol; 1992 Jun; 148(12):4006-11. PubMed ID: 1376348
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The development of synthetic antitumour vaccines from mucin glycopeptide antigens.
    Gaidzik N; Westerlind U; Kunz H
    Chem Soc Rev; 2013 May; 42(10):4421-42. PubMed ID: 23440054
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Epitope selection and development of peptide based vaccines to treat cancer.
    Celis E; Sette A; Grey HM
    Semin Cancer Biol; 1995 Dec; 6(6):329-36. PubMed ID: 8938271
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection.
    van der Most RG; Sette A; Oseroff C; Alexander J; Murali-Krishna K; Lau LL; Southwood S; Sidney J; Chesnut RW; Matloubian M; Ahmed R
    J Immunol; 1996 Dec; 157(12):5543-54. PubMed ID: 8955205
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Artificial protein vaccines with predetermined tertiary structure: application to anti-HIV-1 vaccine design.
    Eroshkin AM; Zhilkin PA; Shamin VV; Korolev S; Fedorov BB
    Protein Eng; 1993 Nov; 6(8):997-1001. PubMed ID: 7508628
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Foot and mouth disease virus polyepitope protein produced in bacteria and plants induces protective immunity in guinea pigs.
    Andrianova EP; Krementsugskaia SR; Lugovskaia NN; Mayorova TK; Borisov VV; Eldarov MA; Ravin NV; Folimonov AS; Skryabin KG
    Biochemistry (Mosc); 2011 Mar; 76(3):339-46. PubMed ID: 21568869
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Versatile RHDV virus-like particles: incorporation of antigens by genetic modification and chemical conjugation.
    Peacey M; Wilson S; Baird MA; Ward VK
    Biotechnol Bioeng; 2007 Dec; 98(5):968-77. PubMed ID: 17546687
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Synthetic peptide vaccines: unexpected fulfillment of discarded hope?
    Meloen RH; Langeveld JP; Schaaper WM; Slootstra JW
    Biologicals; 2001; 29(3-4):233-6. PubMed ID: 11851321
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Orientation of epitopes influences the immunogenicity of synthetic peptide dimers.
    Cox JH; Ivanyi J; Young DB; Lamb JR; Syred AD; Francis MJ
    Eur J Immunol; 1988 Dec; 18(12):2015-9. PubMed ID: 2464496
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
    Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
    Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Mimicry of viral epitopes with retro-inverso peptides of increased stability.
    Benkirane N; Guichard G; Briand JP; Muller S; Brown F; Van Regenmortel MH
    Dev Biol Stand; 1996; 87():283-91. PubMed ID: 8854029
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Multivalent glyco(cyclo)peptides.
    Galan MC; Dumy P; Renaudet O
    Chem Soc Rev; 2013 Jun; 42(11):4599-612. PubMed ID: 23263159
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
    Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
    J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Design of immunogens as components of a new generation of molecular vaccines.
    Loktev VB; Ilyichev AA; Eroshkin AM; Karpenko LI; Pokrovsky AG; Pereboev AV; Svyatchenko VA; Ignat'ev GM; Smolina MI; Melamed NV; Lebedeva CD; Sandakhchiev LS
    J Biotechnol; 1996 Jan; 44(1-3):129-37. PubMed ID: 8717396
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Synthetic approaches to construct viral capsid-like spherical nanomaterials.
    Matsuura K
    Chem Commun (Camb); 2018 Aug; 54(65):8944-8959. PubMed ID: 29872788
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The core antigen of hepatitis B virus as a carrier for immunogenic peptides.
    Murray K; Shiau AL
    Biol Chem; 1999 Mar; 380(3):277-83. PubMed ID: 10223329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.